+++ News Biophan +++ 2$ je share - 500 Beiträge pro Seite

[maxeddi]

Biophan Sells One Million Shares of Common Stock to SBI for $2 Million; Financing to Fund Company\'s Development Objectives and Continue Expansion of Marketing Efforts

ROCHESTER, N.Y.--(BUSINESS WIRE)--May 19, 2006--

Biophan Technologies, Inc. (OTCBB: BIPH; FWB: BTN), a developer of next-generation medical technology, announced today that it has exercised a call requiring SBI Brightline XI, LLC to purchase 1 million shares of Biophan Common Stock at a price of $2 per share, as part of its financing agreement with SBI. Under the financing agreement, Biophan has the right, at any time at its sole discretion, to require SBI to purchase up to 9 million more shares of Common Stock at prices ranging from $2 to $4 per share. If the facility is fully utilized, the Company would receive aggregate proceeds of $30 million, at an average price of $3 per share.

"We are pleased to finally be moving forward with this critical component of our business plan," stated Michael Weiner, Biophan CEO. "It will give us access to the capital needed to meet our development objectives in several critical markets and to continue the expansion of our marketing efforts."

The activities to be supported by this funding will advance Biophan\'s internal research and development for safe and image compatible products and will further enhance the Company\'s strategic relationships, including:

-- Licensing agreement with Boston Scientific (NYSE: BSX);

-- Cooperative Research and Development Agreement (CRADA) with
the U.S. Food and Drug Administration (FDA) to research and
define methods for measuring MRI safety of medical implants,
focusing on the leads used with cardiac pacemakers,
defibrillators, and neurostimulators;

-- Myotech\'s MYO-VAD(TM), a ventricular assist device (VAD),
which does not contact blood, reducing the potential for
complications that plague existing VADs;

-- Space Act Agreement with NASA for the development of
implantable power systems using body heat vs. chemical
batteries, and the Company\'s plan to bring its multiple
technology platforms to market;

-- Negotiations for a strategic research collaboration between
Siemens\' Medical Solutions MRI Division in Europe and Biophan
Europe GmbH, designed to provide new solutions in the growing
field of interventional MRI medicine and MRI-assisted
minimally invasive surgeries; and

-- Collaboration with NaturalNano on the development of novel
nanomaterials to enable improved drug delivery.

[FutureTrend]

30 Mille?? Das ist 1/3 des Börsenwertes!

FT

[maxeddi]

?Ist an Biophan nicht auch Softbank beteiligt?

[naschu72.]